Article
CYP3A5 and ABCB1 polymorphisms in donor and recipient: impact on Tacrolimus dose requirements and clinical outcome after renal transplantation.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association - 1 Sept 2011
Glowacki François, Lionet Arnaud, Buob David, Labalette Myriam, Allorge Delphine, Provôt François, Hazzan Marc, Noël Christian, Broly Franck, Cauffiez Christelle
Abstract excerpt
BACKGROUND: The effect of potentially relevant genetic polymorphisms, CYP3A5 6986A>G and ABCB1 3435C>T, on Tacrolimus pharmacokinetics and graft clinical outcome was investigated in donor and recipient DNA samples from 209 kidney transplant patients. METHODOLOGY/PRINCIPAL FINDINGS: The mean follow-up was 21.8 ± 9 months. The Tacrolimus dose, trough blood concentrations (C0) and C0/dose ratio were only...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
